Trends in Pharmacological Sciences

Article	Citations
Subscription and Copyright Information	690
Subscription and Copyright Information	445
Subscription and Copyright Information	277
Subscription and Copyright Information	183
Advisory Board and Contents	174
Structural asymmetry in FGF23 signaling	162
Subscription and Copyright Information	161
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	153
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	146
Muscarinic receptors: from clinic to bench to clinic	139
Shearing of surface mucin saps tumor cell strength	136
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	122
Targeting of Potassium Channels in Cardiac Arrhythmias	111
Direct in vivo CAR T cell engineering	107
Structural pharmacology and mechanisms of GLP-1R signaling	107
Targeting complement in neurodegeneration: challenges, risks, and strategies	101
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	95
Compstatins: the dawn of clinical C3-targeted complement inhibition	94
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	93
Peptides as a therapeutic strategy against Klebsiella pneumoniae	87
Therapeutic inhibition of ferroptosis in neurodegenerative disease	84
Advisory Board and Contents	81
Advisory Board and Contents	81
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	79
Phenotypic approaches for CNS drugs	75

HSV-1 as a gene delivery platform for cancer gene therapy	72
A smart hospital-driven approach to precision pharmacovigilance	72
Ribosome-directed cancer therapies: the tip of the iceberg?	68
Advisory Board and Contents	65
A deep dive into degrader-induced protein-protein interfaces	63
Leveraging human microbiomes for disease prediction and treatment	62
Emerging strategies for beta cell transplantation to treat diabetes	60
siRNA drug Leqvio (inclisiran) to lower cholesterol	60
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	60
Genetically engineered loaded extracellular vesicles for drug delivery	58
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	58
Engineering ACE2 decoy receptors to combat viral escapability	57
A perspective on psychedelic teratogenicity: the utility of zebrafish models	57
Advisory Board and Contents	57
Suzetrigine for moderate to severe acute pain	55
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	55
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	52
Close to a year in TIPS’ saddle – I am optimistic	52
Subscription and Copyright Information	52
Thriving as members of under-represented groups in pharmacology-related careers	51
Lipoxygenases in chronic liver diseases: current insights and future perspectives	50
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	49
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	49
Could dexmedetomidine be repurposed as a glymphatic enhancer?	49
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	48
Mentoring future science leaders to thrive	47
The structure, function, and pharmacology of MRGPRs	46
Advancing non-destructive analysis of 3D printed medicines	46
Emerging approaches to induce immune tolerance to therapeutic proteins	46
The promise of targeted protein degradation approaches	44
Advisory Board and Contents	44
Building unconventional G protein-coupled receptors, one block at a time	43
Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension	42
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
Fragment-based drug design facilitates selective kinase inhibitor discovery	39
Salt-inducible kinases: new players in pulmonary arterial hypertension?	39
The road less traveled: activating an oncogenic kinase	39
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	39
Promising neuroimmune targets and drugs for CNS diseases	38
Advisory Board and Contents	38
Subscription and Copyright Information	38
A novel function of the M2 muscarinic receptor	38
The end of the beginning in understanding SLC22 polyspecificity	36
Monkeypox: potential vaccine development strategies	35
Targeting intracellular protein–protein interactions with macrocyclic peptides	35
Frizzleds act as dynamic pharmacological entities	34
Validation of agent-based models of surface receptor oligomerisation	34
Decoding pseudouridine: an emerging target for therapeutic development	33
Nanocarriers for oral delivery of biologics: small carriers for big payloads	33

Advisory Board and Contents	33
BTK inhibitors: past, present, and future	33
Metabolic regulation in normal and leukemic stem cells	31
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	31
Recent advances in generative biology for biotherapeutic discovery	31
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	31
Demographic diversity in platelet function and response to antiplatelet therapy	30
Development of PROTACs using computational approaches	30
Engineered antibody fusion proteins for targeted disease therapy	29
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	28
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	28
Eflornithine for treatment of high-risk neuroblastoma	28
Circulating tumor cells in precision medicine: challenges and opportunities	28
A novel anticancer pharmacological agent targeting mitochondrial complex I	27
Subscription and Copyright Information	27
Tackling chronic kidney disease in diabetic patients with finerenone	27
GPR35: from enigma to therapeutic target	27
Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology	27
Subscription and Copyright Information	27
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	27
Visceral obesity and HFpEF: targets and therapeutic opportunities	26
Subscription and Copyright Information	26
Targeting sensory neuron GPCRs for peripheral neuropathic pain	25
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	25
Harnessing associative learning paradigms to optimize drug treatment	25
High-power screening (HPS) empowered by DNA-encoded libraries	24
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	24
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	24
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	24
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	24
Biologics and cardiac disease: challenges and opportunities	24
Boosting CAR-T cell therapy through vaccine synergy	24
Recent advancements in vaccine research and development	23
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	23
Neutrophil extracellular traps in wound healing	23
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	23
Taming PRMT5–adaptor protein interactions	23
Subscription and Copyright Information	23
Teaching an old dog new tricks: repurposing β-lactams	23
GABAA receptors as targets for treating affective and cognitive symptoms of depression	22
Challenges and opportunities associated with rare-variant pharmacogenomics	22
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	22
NLRP3 and pyroptosis blockers for treating inflammatory diseases	22
Circadian biology to advance therapeutics for mood disorders	21
Advisory Board and Contents	20
Partial agonists go molecular	20
Potential for targeting small heat shock protein modifications	20
Glymphatic-stagnated edema induced by traumatic brain injury	19
Targeted protein degrader development for cancer: advances, challenges, and opportunities	19
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Membrane protein production and formulation for drug discovery	19
Odorant receptors as potential drug targets	19
GPCR-dependent and -independent arrestin signaling	18
Microfluidic technologies for drug discovery and development: friend or foe?	18
The structure and function of YTHDF epitranscriptomic m6A readers	18
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	18
Bridging the gap in neuropsychiatric translational research	17
Advisory Board and Contents	17
Advisory Board and Contents	17
Leveraging VGLUT3 Functions to Untangle Brain Dysfunctions	17
Hans Jürg Schatzmann (1924–2021)	17
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	16
Electroceuticals: emerging applications beyond the nervous system and excitable tissues	16
Thapsigargin: key to new host-directed coronavirus antivirals?	16
Subscription and Copyright Information	16
Glaucoma: neuroprotection with NAD-based therapeutic interventions	16
Malolactone strikes: K-Ras-G12D's Achilles' heel	16
Harnessing deep learning for enhanced ligand docking	16
Emerging epigenetic insights into aging mechanisms and interventions	16
Advancing small-molecule drug discovery by encoded dual-display technologies	16
Leveraging non-enzymatic functions of LSD1 for novel therapeutics	15
Mitochondrial dynamics proteins as emerging drug targets	15
Learning from natural design for local anesthetic delivery	15
Structural perspective of class B1 GPCR signaling	15
NET-targeted therapy: effects, limitations, and potential strategies to enhance treatment efficacy	15
Screening strategies for identifying RNA- and ribonucleoprotein-targeted compounds	15
Advisory Board and Contents	14
Subscription and Copyright Information	14
Advisory Board and Contents	14
Current landscape of preclinical models of diabetic cardiomyopathy	14

Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics	14
Apart, together: reflections on the COVID-19 pandemic	14
Safety of medicines and vaccines – building next generation capability	14
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	14
Subtyping for pancreatic cancer precision therapy	14
Celiac disease: mechanisms and emerging therapeutics	14
Advisory Board and Contents	14
Advisory Board and Contents	14
Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation	14
Multiple hERG channel blocking pathways: implications for macromolecules	14
Reactive chemistry for covalent probe and therapeutic development	13
Advisory Board and Contents	13
Targeting chromosomal instability and aneuploidy in cancer	13
Isoform-selective targeting of PI3K: time to consider new opportunities?	13
TNIK’s emerging role in cancer, metabolism, and age-related diseases	13
Subscription and Copyright Information	13
Advisory Board and Contents	13
Endometriosis: cannabidiol therapy for symptom relief	13
A mechanism for ligand-dependent activation of AHR	13
Advisory Board and Contents	12
Present and future of microglial pharmacology	12
Targeting galectin-3 in inflammatory and fibrotic diseases	12
Targeting sialylation to treat central nervous system diseases	12
Engineering extracellular vesicles for diagnosis and therapy	12
Recent breakthroughs and future directions in drugging aquaporins	12
Nanodelivery of cGAS-STING activators for tumor immunotherapy	12
Subscription and Copyright Information	12
IRAK4: potential therapeutic target for airway disease exacerbations	11
Subscription and Copyright Information	11
Advisory Board and Contents	11
Paving the way for designing drugs targeting TMEM16A	11
Casimersen for the treatment of Duchenne muscular dystrophy	11
Structural snapshot of a β-arrestin-biased receptor	10
Mutations in muscle-type creatine kinase impact HIV prevention	10
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	10
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research	10
Subscription and Copyright Information	10
Unifying mechanism behind the onset of acquired epilepsy	10
Repurposing trifluoperazine for glioblastoma treatment	10
Fezolinetant for menopausal hot flashes and night sweats	10
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	10
Subscription and Copyright Information	10
Giving ERK a jERK from the endosome	10
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads	10
Advisory Board and Contents	10
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities	9
Therapeutic targeting of exportin-1 beyond nuclear export	9
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain	9
VMAT structures reveal exciting targets for drug development	9
Efflux Limits Tumor Drug Delivery Despite Disrupted BBB	9
Iron metabolism: pathophysiology and pharmacology	9
A quick guide to networking for scientists	9
Targeting neurological abnormalities in lysosomal storage diseases	9
Heterobifunctional small molecules to modulate RNA function	9
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	9
Subscription and Copyright Information	9
Cholesterol – the devil you know; ceramide – the devil you don’t	9
The structure and function of olfactory receptors	8
Targeting TRPM channels for cerebral ischemia–reperfusion injury	8
Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development	8
Current views on N-glycolylneuraminic acid in therapeutic recombinant proteins	8
Emerging paradigms and recent progress in targeting ErbB in cancers	8
The potential of long noncoding RNA therapies	8
Subscription and Copyright Information	7
Some assembly required: a single-RNA vaccine against enterovirus-D68	7
Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment	7
Emerging mechanisms and therapeutics in inflammatory muscle diseases	7
PPAR agonists for the treatment of neuroinflammatory diseases	7
Subscription and Copyright Information	7
Regulation of drug-metabolizing enzymes by sex-related hormones: clinical implications for transgender medicine	7
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies	6
Data and AI-driven synthetic binding protein discovery	6
Hypothalamic AMPK as a possible target for energy balance-related diseases	6
Subscription and Copyright Information	6
Chromosome-scale genomes throw light on plant drug biosynthesis	6
Mitochondrial quality control: prime targets for antiviral therapy?	6
Subscription and Copyright Information	6
Advances in cell therapy: progress and challenges in hematological and solid tumors	6
Targeting Fks1 proteins for novel antifungal drug discovery	6
A decoy mutant ACE2 designed to reduce COVID-19	6
Leveraging spatial omics for the development of precision sarcoma treatments	6
Glycine: a long-sought novel ligand for GPR158	6
Targeting solute carriers to modulate receptor–ligand interactions	6
Targeting the mitochondrial chaperone TRAP1: strategies and therapeutic perspectives	6
ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics	6
How can quantum computing be applied in clinical trial design and optimization?	6
Enhancing oncogenic signaling to kill cancer cells	6
The future of neuroimmunology research for CNS disease therapeutics	5
Efferocytosis in inflammatory bone disorders	5
Advances and challenges in therapeutic targeting of NRF2	5
Advisory Board and Contents	5
Ganaxolone for management of seizures associated with CDKL5 deficiency disorder	5
Targeting mitochondrial dynamics and redox regulation in cardiovascular diseases	5
Advisory Board and Contents	5
Electrophilic Natural Products as Drug Discovery Tools	5